^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CLDN6-CAR-NK cell therapy

i
Other names: CLDN6-CAR-NK cell therapy, Claudin6 targeting CAR-NK cells
Associations
Company:
Second Affiliated Hospital of Guangzhou Medical University
Drug class:
NK cell stimulant, CLDN6 inhibitor
Related drugs:
Associations
8ms
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. (PubMed, Int J Biol Sci)
More importantly, CAR-NK cells combined with immune checkpoint inhibitors, anti-PD-L1, could synergistically enhance the antitumor efficacy of CLDN6-targeted CAR-NK cells. These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CLDN6 (Claudin 6) • NKG2D (killer cell lectin like receptor K1)
|
CLDN6 expression • CLDN6 positive
|
CLDN6-CAR-NK cell therapy
over2years
CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=40, Recruiting, Second Affiliated Hospital of Guangzhou Medical University
New P1/2 trial
|
CLDN6 (Claudin 6)
|
CLDN6 expression • CLDN6 positive
|
CLDN6-CAR-NK cell therapy